SwingTrade Member Forum

[umiak]

CFRX -- their P2 trial represents one of the new faces in the infectious disease battle. I bought a reasonable amount yesterday, early on purpose.

CF-301 has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia. https://www.contrafect.com/pipeline/overview

Lysins are enzymes that digest the bacterial cell wall and kill bacteria rapidly upon contact, much faster than conventional antibiotics which typically require time for bacterial metabolism to occur before killing bacteria or stopping their growth. Other features which differentiate our lysins from standard antibiotics include antimicrobial activity against antibiotic-resistant bacteria, specificity for target bacteria while preserving the healthy microbiome, and the ability to clear biofilms which can shield bacteria from destruction. In addition, lysins act synergistically with standard of care antibiotics and can reduce the development of resistance to these antibiotics when administered concomitantly. Lysins themselves have very low propensity for resistance.

https://www.contrafect.com/technology/overview